We are live on
!
Find out more
TC
Tavio Capital Portfolio holdings
AUM
$75.4M
1-Year Est. Return
27.99%
This Fund
S&P 500
This Quarter
Est. Return
+10.49%
1 Year Est. Return
+27.99%
3 Year Est. Return
+81.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$195M
AUM Growth
+$89.5M
(+84%)
Cap. Flow
+$81M
Cap. Flow
% of AUM
41.45%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
8
New
4
Increased
2
Reduced
1
Closed
1
Top Buys
| 1 |
Boston Scientific
BSX
|
+$34M |
| 2 |
Elevance Health
ELV
|
+$33.7M |
| 3 |
Universal Health Services
UHS
|
+$16M |
| 4 |
Travere Therapeutics
TVTX
|
+$5.75M |
| 5 |
Humana
HUM
|
+$2.75M |
Top Sells
| 1 |
McKesson
MCK
|
+$10.3M |
| 2 |
WBA
Walgreens Boots Alliance
WBA
|
+$1.14M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Humana
HUM
$48B
| $43.2M | 22.1% |
209,519
+13,278
| +7% | +$2.75M |
|
|
2
Elevance Health
ELV
$80.9B
| $35.1M | 17.95% |
+212,122
| New | +$33.7M |
|
|
3
Boston Scientific
BSX
$65.4B
| $34.7M | 17.77% |
+1,396,441
| New | +$34M |
|
|
WBA
4
DELISTED
Walgreens Boots Alliance
WBA
| $34.4M | 17.61% |
414,374
-13,588
| -3% | -$1.14M |
|
5
Centene
CNC
$32.8B
| $25.8M | 13.21% |
724,710
+8,342
| +1% | +$279K |
|
|
6
Universal Health Services
UHS
$9.15B
| $16.8M | 8.6% |
+135,021
| New | +$16M |
|
|
7
Travere Therapeutics
TVTX
$5.27B
| $5.43M | 2.78% |
+293,923
| New | +$5.75M |
|
|
8
McKesson
MCK
$98.5B
| – | – |
-73,112
| Closed | -$10.3M |
|
Similar funds
PC
EGPO
AIS
MCMT
NBG
FC
SCM
MVM
Tavio Capital's Q1 2017 Portfolio in Review
As of Q1 2017, Tavio Capital held 8 positions worth $195M, up 84% from $106M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Tavio Capital deployed $81M of net new capital in Q1 2017, opening 4 new positions and adding to 2 existing holdings. Its largest new stake was Boston Scientific: 1,396,441 shares worth $34.7M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Walgreens Boots Alliance, an estimated $1.14M trimmed.
- Tavio Capital's largest Q1 2017 buy was Boston Scientific: 1,396,441 shares worth $34.7M.
- Tavio Capital added most to Humana in Q1 2017, an estimated $2.75M increase.
- Tavio Capital's biggest Q1 2017 reduction was Walgreens Boots Alliance, cutting an estimated $1.14M.
- Tavio Capital fully exited McKesson in Q1 2017, selling an estimated $10.3M.
- Tavio Capital's ten largest holdings make up 100% of its $195M portfolio in Q1 2017.
- Tavio Capital opened 4 new positions and closed 1 in Q1 2017.
- Tavio Capital's portfolio value rose 84% quarter-over-quarter to $195M.
Based on Tavio Capital's 13F filing for Q1 2017, filed 15 May 2017.